摘要激素受体（HR）阳性人表皮生长因子受体2（HER2）阴性乳腺癌的内分泌治疗已进入靶向联合时代，以细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）为首的众多靶向药物纷纷崭露头角，为HR阳性HER2阴性晚期乳腺癌患者提供了丰富的治疗选择。为适应我国临床诊疗背景、规范靶向药物的合理使用，中国临床肿瘤学会（CSCO）乳腺癌诊疗指南遵循循证医学证据，兼顾药物可及性，形成晚期乳腺癌内分泌分层治疗策略，为临床肿瘤医生提供科学、有序的决策指导。

abstractsThe endocrine therapy of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer has stepped into an era of targeted combination therapy. Many targeted agents, led by cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), have provided abundant treatment options for patients with HR-positive HER2-negative advanced breast cancer. To meet the needs of clinical practice in China and standardize the administration of targeted agents, the stratified endocrine strategy for advanced breast cancer has been proposed by Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines based on medicine evidence and drug accessibility, offering scientific and organized decision-making guidance for clinical oncologists.